文献速递细菌感染、耐药与抗菌药物

杀菌性与抑菌性抗菌药:临床意义、差异及临床实践中的协同潜力

Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本综述基于体外与体内研究,评估杀菌性与抑菌性抗菌药的活性差异及联用时的拮抗或协同效应。结果显示,利奈唑胺和替加环素等特定抑菌药在肺炎、腹腔感染和皮肤软组织感染中临床非劣于杀菌药,部分抑菌药可作为中性粒细胞减少性发热和心内膜炎的挽救治疗,且并非所有抑菌药与杀菌药联用均拮抗。证据多来自观察性研究,需谨慎解读。

要点

  • 利奈唑胺和替加环素等特定抑菌药在肺炎、腹腔感染和皮肤软组织感染中临床非劣于杀菌药。
  • 部分抑菌药可作为中性粒细胞减少性发热和心内膜炎等严重感染的挽救治疗。
  • 并非所有抑菌药与杀菌药联用均拮抗,利奈唑胺与利福平等联用已在临床使用。

核心结论

  • 特定抑菌药如利奈唑胺和替加环素在多种感染中临床非劣于杀菌药,部分抑菌药可作为严重感染的挽救治疗,且并非所有抑菌药与杀菌药联用均拮抗。
  • 证据多来自观察性研究,需谨慎解读,需要随机对照试验评估其有效性和联用效果,尤其是在抗菌药物耐药上升的背景下。

研究设计与样本

  • 本综述旨在基于体外和体内研究评估杀菌性与抑菌性抗菌药的抗菌活性差异,并检验其拮抗或协同效应。

主要发现

  • 特定抑菌药如利奈唑胺和替加环素在肺炎、腹腔感染和皮肤软组织感染等多种感染中临床非劣于杀菌药。
  • 研究支持使用多种抑菌药作为中性粒细胞减少性发热和心内膜炎等严重感染的挽救治疗。
  • 并非所有抑菌药与杀菌药的联用均表现为拮抗,利奈唑胺与利福平等多种联用已在临床使用。

关键数值与推荐

  • 抗菌活性可通过MBC/MIC比值和时间-杀菌曲线等方法分类为杀菌性或抑菌性,但这些定义仅适用于特定实验室条件,可能与临床环境不同。
  • 特定细菌或感染介质等因素可影响抗生素作用,许多抗菌药兼具杀菌和抑菌活性。

临床怎么用

  • 特定抑菌药如利奈唑胺和替加环素在肺炎、腹腔感染和皮肤软组织感染中临床非劣于杀菌药。
  • 多种抑菌药可作为中性粒细胞减少性发热和心内膜炎等严重感染的挽救治疗。
  • 利奈唑胺与利福平等抑菌药与杀菌药的联用已在临床使用。

局限性

  • 证据多来自观察性研究,需谨慎解读。
  • 需要随机对照试验评估抑菌药与杀菌药的有效性和联用效果,尤其是在抗菌药物耐药上升的背景下。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibacterial activity can be classified as either bactericidal or bacteriostatic, using methods such as the MBC/MIC ratio and time-kill curves. However, such categorization has proven challenging in clinical practice, as these definitions only apply under specific laboratory conditions, which may differ from clinical settings. Several factors, such as the specific bacteria or infectious medium, can affect the action of antibiotics, with many antibacterials exerting both activities. These definitions have also led to the belief that bactericidal antibacterials are superior to bacteriostatic, especially in more severe cases, such as endocarditis, neutropenia and bacteraemia. Additionally, current dogma dictates against the combination of bactericidal and bacteriostatic antibacterials in clinical practice, due to potential antagonism. This review aimed to assess the differences in antibacterial activity of bactericidal and bacteriostatic antibacterials based on in vitro and in vivo studies and examine their antagonistic or synergistic effects. Our findings show that specific bacteriostatic agents, such as linezolid and tigecycline, are clinically non-inferior to bactericidals in multiple infections, including pneumonia, intra-abdominal infections, and skin and soft tissue infections. Studies also support using several bacteriostatic agents as salvage therapies in severe infections, such as neutropenic fever and endocarditis. Additionally, not all combinations of bacteriostatic and bactericidal agents appear to be antagonistic, with many combinations, such as linezolid and rifampicin, already being used. The findings should be interpreted with caution, as most evidence is from observational studies and there is a need for randomized controlled trials to assess their effectiveness and combinations, especially within the context of rising antimicrobial resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ishak A, Mazonakis N, Spernovasilis N, et al. Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice. J Antimicrob Chemother. 2025. PMID: 39471409. doi:10.1093/jac/dkae380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。